Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195845 · ClinicalTrials.gov registry record · Phase 4
A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
A Phase 4 study of Bipolar Disorder, sponsored by Cambridge Health Alliance.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00195845 is a Phase 4 study of Bipolar Disorder that has completed, run by Cambridge Health Alliance. The registered enrollment target is 30 participants, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00195845, a Phase 4 study of Bipolar Disorder, has completed, sponsored by Cambridge Health Alliance.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if galantamine augmentaion improves cognition in euthymic bipolar patients. In addition, the effect of galantamine on clinical measures of functioning and psychopathology will also be assessed.
Conditions Studied
Interventions
- DRUG Placebos
- DRUG Galantamine
Study Locations (1)
Massachusetts
- Cambridge Health Alliance - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-04 |
| Est. Completion | 2007-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195845
The ClinicalTrials.gov registry entry for NCT00195845 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (91% lower). The listed sponsor is Cambridge Health Alliance, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebos is the first listed.
NCT00195845 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00195845 about?
NCT00195845 is a clinical study titled "A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder". The purpose of this study is to determine if galantamine augmentaion improves cognition in euthymic bipolar patients. In addition, the effect of galantamine on clinical measures of functioning and psychopathology will also be assessed.
What is the current status of trial NCT00195845?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2003-04. Estimated completion is 2007-02.
What conditions does trial NCT00195845 study?
This clinical trial studies the following conditions: Bipolar Disorder.
What interventions are being tested in trial NCT00195845?
The interventions under investigation include: Placebos (DRUG), Galantamine (DRUG).
Who is sponsoring clinical trial NCT00195845?
This trial is sponsored by Cambridge Health Alliance, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00195845 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
COMPLETED · Phase 4
-
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
COMPLETED · Phase 4
-
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
COMPLETED · Phase 4
-
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
COMPLETED · Phase 4
-
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.